Business Wire

GC-AESTHETICS

Share
GC Aesthetics® Announces the Launch of FixNip™: a Total Game-Changer in Breast Reconstruction

GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Healthcare Aesthetic Solutions, announced the launch of an Innovative Nipple Areola Complex (NAC) Reconstruction Implant : FixNip™ NRI .

This unrivalled medical device is the answer to a well-known clinical need of thousands of women around the world. Until now, a variety of surgical techniques are used to try to reconstruct the nipple areola complex with none providing a long term aesthetic solution.

GC Aesthetics® in an exclusive partnership agreement with FixNip LTD is proud of launching FixNip NRI in main European Territories, while the roll-out to Latin America, Central Europe and Asia will be announced later this year.

"We are committed to deliver safe options that establish a newer, higher, and more beneficial standard of care for women who seek to total breast reconstruction. Such technology breakthrough will complete our range of solutions dedicated to women aesthetic healthcare. FixNip by GC Aesthetics is a healthcare game-changer” said Carlos Reis Pinto, CEO of GC Aesthetics®.

With this one-of-a-kind-product GC Aesthetics will spearhead expansion and growth into the Breast Reconstruction Segment, elevating and enhancing current standards.

“The NAC reconstruction procedure should be considered an integral part of the breast reconstructive surgery. It gives women an important psychological contribution and leads a greater well-being, overall sense of self and high satisfaction after being reconstructed. As a leader of the GCA multi-centric safety and efficacy trial, I am highly satisfied with the results” added Prof. Dr. Michael Atlan, renowned French Plastic Surgeon.

The GC Aesthetics FixNip NRI is implanted with a minimally invasive procedure done by a Surgeon in average in 15 minutes. The outcome has been demonstrating a high patient satisfaction with a minimum patient down time and an excellent safety profile.

“At GCA we believe a Total Breast Reconstruction is not only a choice, but a pathway for women to a full recovery after a mastectomy. We are extremely proud of adding this product to our portfolio and what it will represent for Reconstructive and Plastic Surgeons and the lives of thousands of women." Mentioned Fara Naomi Macías, CMO of GCA.

About GC Aesthetics

GC Aesthetics is a long-established global medical technology company that develops, manufactures and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal life journey.

Throughout its 40-year history, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality breast implants for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries, and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness.

The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to surgeons and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv811.12.2025 14:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833. The Statement reflects the growing body of clinical evidence supporting the use of ReActiv8, as well as recent developments in diagnostic coding and reimbursement pathways since ISASS’ 2023 Statement on Restorative Neurostimulation for Chr

SLB Enters Collaboration Agreement to Accelerate New Digital Solutions11.12.2025 14:28:00 CET | Press release

Global energy technology company SLB (NYSE: SLB) signed a strategic collaboration agreement with Shell to develop digital and AI solutions that drive measurable performance and efficiency gains across upstream operations for the company and the wider industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211832051/en/ The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI infrastructure that unifies data and workflows across subsurface, well construction and production in a secure digital environment, using SLB’s Lumi™ data and AI platform. The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI i

Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas11.12.2025 14:00:00 CET | Press release

Parse’s GigaLab to provide industry leading, large-scale, single cell services to support Tahoe’s development of foundational biological datasets Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcoming 300M cell project. Tahoe will use its proprietary Mosaic technology to generate samples consisting of 300M cells from large arrays of disease models, genetically or chemically perturbed. Under this agreement, Parse will apply its Evercode™ chemistry and high-throughput automation to these samples to deliver the largest perturbation-focused single cell dataset ever produced. Parse’s GigaLab, designed specifically for million- to hundred-million-cell projects, has rapidly become an industry benchmark for large-scale, reproducible single cell data generation. The facility integrates high-capacity liquid handling, standardized workflows, and end-to

Xsight Labs X2 Switch to Enable Next-Generation Starlink Satellites and Deliver Gigabit Connectivity11.12.2025 14:00:00 CET | Press release

High-bandwidth, ultra-low-power chip is leveraged for Starlink V3 satellites and future next-generation communication systems. News Highlights: Xsight’s X2 switch enables Starlink V3 satellite Delivers the performance required for rapid data processing, stable telemetry, and real-time operational responsiveness for Starlink X2’s flexible, programmable architecture adapts seamlessly to diverse orbital and ground-based networking workloads Xsight Labs, an innovator in high-performance connectivity silicon, today announced that Starlink, the world’s most advanced satellite constellation in low-Earth orbit, delivering broadband, will leverage the Xsight X2 Programmable Ethernet switch to serve as the high-speed networking core for its next-generation Starlink V3 satellites. Each V3 Starlink satellite is designed to deliver more than 1 terabit per second (Tbps) of fronthaul throughput, more than 10× the capacity delivered by Starlink V2 Mini satellites, and about 160 gigabits per second (Gb

Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 13:00:00 CET | Press release

ACI’s Top Ten Payments Predictions for 2026 urges payments leaders to act amid structural shifts in global payments Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are en

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye